The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...

Strasbourg, France, January 23, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced ...

The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a large DNA payload into T cells in vivo.

Endometrial cancer is the most common gynecologic cancer in the United States and is one of the few cancers in which survival rates have steadily declined over the last few decades. The most ...